Superworth

Amgen forward PE AMGN

Share price divided by analysts' consensus earnings for the next twelve months, since 1994.

Today, Nov 3, 2026
19.8×
10-year median
14.5×
Against its 10-year history
100th
percentile: 0 is its lowest day, 100 its highest
10-year range
11.7× to 19.7×
Peer median
18.7×

Amgen's forward PE is 19.8× as of Nov 3, 2026.

That is above its ten-year median of 14.5×, higher than on 100% of days in the last ten years.

Over that time it ranged from 11.7× in May 2019 to 19.7× in Oct 2026.

The median for 8 large drugmakers of a similar size is 18.7×.

Forward PE over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far19.7×14.3×19.7×
202515.9×13.3×16.8×
202413.4×13.4×17.3×
202315.4×12.3×16.1×
202215.4×12.9×16.8×
202113.2×11.8×16.1×
202014.6×12.7×17.1×
201916.2×11.7×16.3×
201813.9×12.9×15.5×
201713.8×12.8×15.2×
201612.8×11.8×16.5×
201517.1×15.5×21.2×
201420.5×14.7×21.3×
201315.9×12.9×17.3×
201213.6×12.1×14.7×
201112.7×10.1×12.7×
201011.8×11.0×13.2×
200911.9×10.3×13.8×
200813.1×10.2×15.3×
200712.6×12.6×18.3×

Against its peers

Companies in Drug Manufacturers - General nearest Amgen's size, closest first, today.

CompanyForward PE
AMGNAmgen19.8×
GILDGilead Sciences19.8×
PFEPfizer11.2×
MRKMerck17.2×
BMYBristol-Myers Squibb9.8×
ABBVAbbVie18.3×
JNJJohnson & Johnson23.9×
LLYEli Lilly and30.9×
BIIBBiogen19.0×
Peer median18.7×

Where Amgen ranks

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Amgen

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.